Driehaus Capital SVRA Position
Exited3-Fund ConvergenceDriehaus Capital exited their position in Savara Inc. (SVRA) in Q3 2025, after holding the stock for 2 quarters.
The position was first reported in Q2 2025 and has been tracked across 2 quarterly 13F filings.
SVRA is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Molgramostim in 440 days (Jun 30, 2027), making the timing of Driehaus's position particularly relevant.
Short interest stands at 13.4% of float with 17.1 days to cover, indicating significant bearish positioning against the stock.
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Full company profile →Short Interest
13.4%
17.1 days to cover
Driehaus Capital SVRA Position History
Frequently Asked Questions
Does Driehaus Capital own SVRA?
No. Driehaus Capital exited their position in Savara Inc. (SVRA) in Q3 2025. They previously held the stock for 2 quarters.
How many hedge funds own SVRA?
3 specialist biotech hedge funds currently hold SVRA, including Deerfield Management, RTW Investments, Perceptive Advisors. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy SVRA?
Driehaus Capital's position in SVRA was first reported in Q2 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's SVRA position increasing or decreasing?
Driehaus Capital completely exited their SVRA position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
SVRACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →